ES2664095T3 - Fragmentos de anticuerpos monoméricos diseñados mediante ingeniería genética - Google Patents

Fragmentos de anticuerpos monoméricos diseñados mediante ingeniería genética Download PDF

Info

Publication number
ES2664095T3
ES2664095T3 ES13824174.0T ES13824174T ES2664095T3 ES 2664095 T3 ES2664095 T3 ES 2664095T3 ES 13824174 T ES13824174 T ES 13824174T ES 2664095 T3 ES2664095 T3 ES 2664095T3
Authority
ES
Spain
Prior art keywords
fab
variants
monomeric
polypeptide
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13824174.0T
Other languages
English (en)
Spanish (es)
Inventor
Weili DUAN
Ronald W. KRIZ
Ishino TETSUYA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Application granted granted Critical
Publication of ES2664095T3 publication Critical patent/ES2664095T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ES13824174.0T 2012-12-07 2013-11-25 Fragmentos de anticuerpos monoméricos diseñados mediante ingeniería genética Active ES2664095T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261734841P 2012-12-07 2012-12-07
US201261734841P 2012-12-07
PCT/IB2013/060384 WO2014087299A1 (en) 2012-12-07 2013-11-25 Engineered monomeric antibody fragments

Publications (1)

Publication Number Publication Date
ES2664095T3 true ES2664095T3 (es) 2018-04-18

Family

ID=50001048

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13824174.0T Active ES2664095T3 (es) 2012-12-07 2013-11-25 Fragmentos de anticuerpos monoméricos diseñados mediante ingeniería genética

Country Status (6)

Country Link
US (1) US10233229B2 (enExample)
EP (1) EP2928917B1 (enExample)
JP (1) JP6396313B2 (enExample)
CA (1) CA2892756C (enExample)
ES (1) ES2664095T3 (enExample)
WO (1) WO2014087299A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10745463B2 (en) 2013-11-18 2020-08-18 University Of Maryland, Baltimore Hyper-glycosylated antibodies with selective Fc receptor binding
US20160130324A1 (en) 2014-10-31 2016-05-12 Shire Human Genetic Therapies, Inc. C1 Inhibitor Fusion Proteins and Uses Thereof
SG11201808723UA (en) 2016-04-04 2018-11-29 Shire Human Genetic Therapies Conjugated c1 esterase inhibitor and uses thereof
JP7556687B2 (ja) 2017-02-24 2024-09-26 中外製薬株式会社 薬学的組成物、抗原結合分子、治療方法、およびスクリーニング方法
WO2019023097A1 (en) * 2017-07-26 2019-01-31 Smet Pharmaceutical Inc ASYMMETRIC BISPECIFIC ANTIBODIES AND THEIR USE
WO2020221450A1 (en) * 2019-04-30 2020-11-05 Humabs Biomed Sa Antibodies and methods for treatment of influenza a infection

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
GB2183662B (en) 1985-04-01 1989-01-25 Celltech Ltd Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
US6517529B1 (en) 1999-11-24 2003-02-11 Radius International Limited Partnership Hemodialysis catheter
KR100545720B1 (ko) * 2004-05-31 2006-01-24 메덱스젠 주식회사 당화된 면역글로불린 및 이를 포함하는 면역접합체
US7393662B2 (en) * 2004-09-03 2008-07-01 Centocor, Inc. Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
US20060074225A1 (en) 2004-09-14 2006-04-06 Xencor, Inc. Monomeric immunoglobulin Fc domains
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
KR101866623B1 (ko) 2005-11-28 2018-07-04 젠맵 에이/에스 재조합 １가 항체 및 그의 제조 방법
EP2152751A1 (en) 2007-05-31 2010-02-17 Genmab A/S Fusion or linked proteins with extended half life
CA2766166A1 (en) 2009-07-08 2011-01-13 Amgen Inc. Design of stable and aggregation free antibody fc molecules through ch3 domain interface engineering
EP2494061B1 (en) 2009-10-29 2017-01-25 Janssen Biotech, Inc. Antibody glycosylation variants
EP2504360B1 (en) 2009-11-23 2018-08-15 Amgen Inc. Monomeric antibody fc

Also Published As

Publication number Publication date
US20150322135A1 (en) 2015-11-12
JP6396313B2 (ja) 2018-09-26
EP2928917B1 (en) 2018-02-28
WO2014087299A1 (en) 2014-06-12
CA2892756A1 (en) 2014-06-12
EP2928917A1 (en) 2015-10-14
WO2014087299A9 (en) 2015-08-27
JP2016505559A (ja) 2016-02-25
CA2892756C (en) 2020-04-14
US10233229B2 (en) 2019-03-19

Similar Documents

Publication Publication Date Title
ES2846748T3 (es) Regiones constantes de cadenas pesadas con unión reducida a receptores Fc gamma
ES2860988T3 (es) Anticuerpos anti-TFR y su uso en el tratamiento de trastornos proliferativos e inflamatorios
ES2694002T3 (es) Polipéptido que comprende una región Fc de IgG1 humana variante
ES2847155T3 (es) Moléculas multiespecíficas que fijan como objetivo CLL-1
JP7189141B2 (ja) Ｔ細胞エンゲージ抗体コンストラクトを含む低ｐＨ医薬組成物
US20250043019A1 (en) TRISPECIFIC ANTIBODY TARGETING CD79b, CD20, AND CD3
WO2020244526A1 (zh) 一种抗ceacam5的单克隆抗体及其制备方法和用途
KR20190141658A (ko) Pd-1 결합 단백질을 포함하는 제제 및 이의 제조 방법
KR20160142332A (ko) 면역활성화 항원 결합 분자
CN117603354A (zh) 具有经修饰的ch2-ch3序列的犬抗体
JP7386877B2 (ja) 新規の抗ｉｆｎａｒ１抗体
US20220089736A1 (en) Immune targeting molecules and uses thereof
AU2021389989A1 (en) Novel conjugate molecules targeting cd39 and tgfβeta
WO2024131962A1 (zh) 新型抗gprc5d抗体
US20250340663A1 (en) Antibody fc variants
JP6396313B2 (ja) 操作された単量体抗体断片
CN118076638A (zh) 新型抗sirpa抗体
WO2018049237A1 (en) Methods and compositions for treatment of lafora disease
US20250188186A1 (en) Ph-selective antibody fc domains
WO2021013269A1 (en) Bifunctional molecules with il-7 activity
CN119285771A (zh) 抗vegfr1抗体及其用途
JP7796005B2 (ja) 抗ｔｒｅｍ－１抗体およびその使用
CN116437949A (zh) 剪切速率降低的抗原结合结构域
WO2022116079A1 (zh) 一种抗ceacam5的人源化抗体及其制备方法和用途
WO2022053054A1 (en) Neutralizing antibodies against sars-cov-2